Cronos Group Inc.

TSX:CRON Stock Report

Market Cap: CA$1.1b

Cronos Group Valuation

Is CRON undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CRON when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CRON (CA$2.79) is trading above our estimate of fair value (CA$0.04)

Significantly Below Fair Value: CRON is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRON?

Key metric: As CRON is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CRON. This is calculated by dividing CRON's market cap by their current revenue.
What is CRON's PS Ratio?
PS Ratio6.9x
SalesUS$111.23m
Market CapUS$773.83m

Price to Sales Ratio vs Peers

How does CRON's PS Ratio compare to its peers?

The above table shows the PS ratio for CRON vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.9x
VRNO Verano Holdings
0.7x5.0%CA$850.9m
TRUL Trulieve Cannabis
1x6.0%CA$1.6b
CL Cresco Labs
0.6x1.9%CA$745.0m
GUD Knight Therapeutics
1.5x5.9%CA$519.1m
CRON Cronos Group
6.9x4.9%CA$1.1b

Price-To-Sales vs Peers: CRON is expensive based on its Price-To-Sales Ratio (6.9x) compared to the peer average (0.9x).

Price to Sales Ratio vs Industry

How does CRON's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

23 CompaniesPrice / SalesEstimated GrowthMarket Cap
AYR.A Ayr Wellness
0.2x2.6%US$82.27m
ACRG.A.U Acreage Holdings
0.08xn/aUS$26.82m
MRV Nuvo Pharmaceuticals
0.2xn/aUS$11.21m
IMCC IM Cannabis
0.2x24.8%US$7.96m
CRON 6.9xIndustry Avg. 0.7xNo. of Companies23PS012345+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CRON is expensive based on its Price-To-Sales Ratio (6.9x) compared to the Canadian Pharmaceuticals industry average (0.7x).

Price to Sales Ratio vs Fair Ratio

What is CRON's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRON PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.9x
Fair PS Ratio0.8x

Price-To-Sales vs Fair Ratio: CRON is expensive based on its Price-To-Sales Ratio (6.9x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CRON forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$2.79
CA$3.44
+23.2%
25.3%CA$5.00CA$2.76n/a6
Nov ’25CA$3.02
CA$3.44
+13.9%
25.3%CA$5.00CA$2.76n/a6
Oct ’25CA$2.87
CA$3.51
+22.1%
23.7%CA$5.00CA$2.80n/a6
Sep ’25CA$3.03
CA$3.52
+16.3%
21.4%CA$5.00CA$2.82n/a7
Aug ’25CA$3.27
CA$3.61
+10.4%
20.6%CA$5.00CA$2.82n/a7
Jul ’25CA$3.19
CA$3.61
+13.2%
20.6%CA$5.00CA$2.82n/a7
Jun ’25CA$3.54
CA$3.74
+5.6%
19.4%CA$5.00CA$2.80n/a7
May ’25CA$3.75
CA$3.57
-4.9%
20.0%CA$5.00CA$2.80n/a7
Apr ’25CA$3.56
CA$3.46
-2.7%
22.7%CA$5.00CA$2.64n/a7
Mar ’25CA$2.75
CA$3.39
+23.3%
24.4%CA$5.00CA$2.64n/a7
Feb ’25CA$2.87
CA$3.49
+21.6%
22.6%CA$5.00CA$2.64n/a7
Jan ’25CA$2.77
CA$3.40
+22.7%
22.9%CA$5.00CA$2.64n/a8
Dec ’24CA$2.83
CA$3.38
+19.3%
23.7%CA$5.00CA$2.46n/a8
Nov ’24CA$2.44
CA$3.32
+36.1%
26.1%CA$5.00CA$2.11CA$3.028
Oct ’24CA$2.71
CA$3.40
+25.6%
25.0%CA$5.00CA$2.11CA$2.879
Sep ’24CA$2.67
CA$3.31
+24.0%
24.7%CA$5.00CA$2.11CA$3.039
Aug ’24CA$2.55
CA$3.40
+33.2%
25.3%CA$5.00CA$2.11CA$3.279
Jul ’24CA$2.61
CA$3.40
+30.2%
25.3%CA$5.00CA$2.11CA$3.199
Jun ’24CA$2.34
CA$3.46
+47.9%
23.8%CA$5.00CA$2.11CA$3.549
May ’24CA$2.55
CA$4.14
+62.3%
31.7%CA$7.00CA$2.86CA$3.759
Apr ’24CA$2.60
CA$4.40
+69.4%
28.0%CA$7.00CA$2.86CA$3.569
Mar ’24CA$2.90
CA$4.40
+51.8%
28.0%CA$7.00CA$2.86CA$2.759
Feb ’24CA$3.33
CA$5.12
+53.9%
37.7%CA$10.00CA$3.38CA$2.8710
Jan ’24CA$3.44
CA$5.19
+51.0%
36.5%CA$10.00CA$3.38CA$2.7710
Dec ’23CA$4.40
CA$5.19
+18.0%
36.5%CA$10.00CA$3.38CA$2.8310
Nov ’23CA$4.42
CA$5.68
+28.4%
44.8%CA$11.00CA$3.00CA$2.4410

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Fennec Pharmaceuticals

US$117.3m

Operates as a biopharmaceutical company in the United States.

FRX

US$6.50

7D

7.6%

1Y

-44.2%

Medexus Pharmaceuticals

CA$52.0m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.15

7D

5.4%

1Y

40.5%

Verano Holdings

CA$850.9m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.32

7D

-12.8%

1Y

-60.6%